close
close

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Study Evaluating Bezisterim in Long-Term COVID Page 1

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Study Evaluating Bezisterim in Long-Term COVID Page 1

Authorization expands the use of bezisterim in a phase 2, placebo-controlled, multicenter study assessing the impact of bezisterim on neurological symptoms associated with long-term COVID

Major milestone achieved ahead of schedule as BioVie is on track to receive an additional $12.6 million from the U.S. Department of Defense and initiate Phase 2 trial